For example, interruption of daily factor VIII infusion given for ITI may lead to reemergence of an inhibitor that had been responding to the tolerance program and may result in the loss of gains previously made at a high cost. Similarly, a patient on prophylaxis with daily bypassing therapy who has experienced benefit in the prevention of joint bleeding may experience recurrent joint bleeding and joint deterioration with an interruption of therapy.